2023/2024 年流感季期间英国初级和二级保健中的疫苗有效性。
Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United Kingdom.
机构信息
Statistics, Modelling and Economics Department, UK Health Security Agency, London, UK.
Clinical and Protecting Health, Public Health Scotland, Glasgow, UK.
出版信息
Influenza Other Respir Viruses. 2024 May;18(5):e13284. doi: 10.1111/irv.13284.
BACKGROUND
We report 2023/2024 season interim influenza vaccine effectiveness for three studies, namely, primary care in Great Britain, hospital settings in Scotland and hospital settings in England.
METHODS
A test negative design was used to estimate vaccine effectiveness.
RESULTS
Estimated vaccine effectiveness against all influenzas ranged from 63% (95% confidence interval 46 to 75%) to 65% (41 to 79%) among children aged 2-17, from 36% (20 to 49%) to 55% (43 to 65%) among adults 18-64 and from 40% (29 to 50%) to 55% (32 to 70%) among adults aged 65 and over.
CONCLUSIONS
During a period of co-circulation of influenza A(H1N1)pdm09 and A(H3N2) in the United Kingdom, evidence for effectiveness of the influenza vaccine in both children and adults was found.
背景
我们报告了三个研究的 2023/2024 季节流感疫苗有效性，分别是英国的初级保健、苏格兰的医院环境和英格兰的医院环境。
方法
采用阴性测试设计来估计疫苗的有效性。
结果
在年龄为 2-17 岁的儿童中，针对所有流感的估计疫苗有效性范围为 63%（95%置信区间为 46%至 75%）至 65%（41%至 79%）；在 18-64 岁的成年人中，针对所有流感的估计疫苗有效性范围为 36%（20%至 49%）至 55%（43%至 65%）；在年龄为 65 岁及以上的成年人中，针对所有流感的估计疫苗有效性范围为 40%（29%至 50%）至 55%（32%至 70%）。
结论
在英国甲型流感 H1N1pdm09 和甲型流感 H3N2 共同流行期间，发现了流感疫苗在儿童和成人中的有效性证据。
Zotero 插件